IGC THC-Drug For Alzheimer's Symptoms Proved Safe & Effective, Pending FDA Approval For More Trials

India Globalization Capital, Inc. (NYSE: IGC) announced Tuesday that it had received positive primary endpoint data for its Phase 1 clinical trial for IGC-AD1, which is a proprietary cannabinoid-based investigational new drug candidate for patients with Alzheimer's disease, which impacts about 50 million people worldwide, out of which roughly 66% are women.

The news came on the heels of the company's recent update on preliminary results from a Phase 1 clinical trial of a THC-drug to treat Alzheimer's symptoms. The results indicated that dosing two or three times per day may be safe for patients, as the first and potentially …

Full story available on Benzinga.com

More IGC THC-Drug For Alzheimer's Symptoms Proved Safe & Effective, Pending FDA Approval For More Trials